Please assess the completion status of the following clinical trial:

Trial Title: Antithrombin III in Infectious Disease Caused by COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. \>18y of age,~2. Subject or proxy who can provide informed consent~3. Positive SARS-COV-2 by Polymerase Chain Reaction (PCR) or as determined by clinical team~EXCLUSION CRITERIA:~1. Adults or Proxy unable to consent~2. Individuals who are not yet adults (infants, children, teenagers)~3. Pregnant women~4. Prisoners~5. Patients expected to die within 24 hours or with a do not resuscitate order,~6. Multi-organ failure,~7. History of hypersensitivity or allergy to any component of the study drug,~8. Ongoing massive surgical or unexplained bleeding,~9. History of bleeding or clotting disorder,~10. Severe traumatic brain injury (Glasgow Coma Scale \<6),~11. Spinal or multiple-trauma,~12. Cancer (incurable/terminal phase) and/or patients receiving palliative care,~13. Enrollment in another concurrent clinical interventional study if considered interfering with this study objectives~14. Per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AT3 less than 100% with SOC plus AT3 supplement (Type: EXPERIMENTAL): Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
- AT3 less than 100% with SOC only (Type: NO_INTERVENTION): Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
- AT3 more than 100% with SOC only (Type: NO_INTERVENTION): Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.

Based on this trial design, predict the completion outcome and termination type (if applicable).